Taligen Therapeutics' Series B - II Round

Taligen Therapeutics raised a round of funding on August 12, 2010.

Taligen Therapeutics is a development-stage biotechnology company. In January 2011, Taligen Therapeutics was acquired by Alexion Pharmaceuticals. The valuation of Taligen Therapeutics was $111 millio…

Articles about Taligen Therapeutics' Series B - II Round: